Latest Melanoma Stories

WESTMINSTER, Md., April 16, 2013 /PRNewswire-USNewswire/ -- The Joanna M. Nicolay Melanoma Foundation (JMNMF) awarded ten $10,000, nationally competitive, "Research Scholar Awards" (RSA) to exceptional graduate student melanoma researchers at leading cancer centers across the U.S. The JMNMF increased funding again in 2013, to significantly enhance the potential for advancements in the melanoma cancer field; and, to increase the number of young scientists choosing melanoma research as...

New Campaign Promotes the Importance of Skin Protection and Melanoma Screening LOS ANGELES / NEW YORK, April 11, 2013 /PRNewswire/ -- Stand Up To Cancer (SU2C), a program of the Entertainment Industry Foundation (EIF), and the Melanoma Research Alliance (MRA) have collaborated on a new television and radio public service announcement starring Emmy® Award-winning celebrity chef Giada De Laurentiis, who tragically lost her brother to melanoma. The PSA is designed to increase awareness...

Universal Pictures, Pale Girl SPEAKS and the Melanoma Research Foundation Announce 2nd Annual Event at Universal Studios on May 4(th) with Sponsors including the Style Network, LA Galaxy and the Los Angeles Times WASHINGTON and LOS ANGELES, April 11, 2013 /PRNewswire-USNewswire/ -- The Melanoma Research Foundation (MRF) and Pale Girl SPEAKS today announced that skin cancer survivor Sheryl Lowe and her husband, actor Rob Lowe, will co-chair the second annual Miles for Melanoma 5K...

For the first time, scientists have demonstrated the mechanism of action of gossypin, a naturally-occurring substance found in fruits and vegetables, as a treatment for melanoma, which causes the majority of deaths from skin cancer. "We identified gossypin as a novel agent with dual inhibitory activity towards two common mutations that are the ideal targets for melanoma treatment," said Texas Biomed's Hareesh Nair, Ph.D. At the moment, there is no single therapeutic agent or combination...

Diverse pipeline reflected in four molecules targeting key cancer pathways WASHINGTON, April 10, 2013 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) unveiled data from four key molecules that represent the next generation of its oncology pipeline at the American Association for Cancer Research (AACR) Annual Meeting held in Washington, D.C. from April 6-10. The data reflect Lilly's diverse oncology pipeline via molecules that target several pathways that are among the most common...

[ Watch the Video: What Do You Know About Melanoma? ] redOrbit Staff & Wire Reports - Your Universe Online More than one-quarter of people diagnosed with melanoma, the deadliest form of skin cancer, fail to wear sunscreen, according to a new Yale University study. Researchers surveyed 171 US melanoma survivors, and found that more than 25 percent never use sunscreen when spending an hour or more in the sun, while 27.3 percent never wear sunscreen at all. Even more...

NKTR-214 Demonstrates Improved Efficacy in Resistant Preclinical Melanoma Model Through Preferential Activation of Tumor Killing Immune Cell Subtype SAN FRANCISCO, April 7, 2013 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today presented positive preclinical data for NKTR-214, a novel cancer immunotherapy which targets the IL-2 receptor complex, at the 2013 American Association for Cancer Research (AACR) Annual Meeting. NKTR-214 is a new immunocytokine that is being developed...

Individualized Genomic Testing Allows for Tailored Cancer Treatment, New Drug Research PHILADELPHIA, April 6, 2013 /PRNewswire-USNewswire/ -- Just like a massive iceberg jutting out of the ocean, many of cancer's genetic underpinnings remain hidden under the surface, impossible to predict or map from above. The foreboding shadows and shapes that appear on CT scans and MRIs - and even in the field that doctors see when they zoom in to look at cancer cells under a high-powered...

-- Genomic, Molecular Findings by CHOP Researchers Will Help Inform Personalized Medicine -- PHILADELPHIA, March 26, 2013 /PRNewswire-USNewswire/ -- Pediatric researchers, investigating the biology of brain tumors in children, are finding that crucial differences in how the same gene is mutated may call for different treatments. A new study offers glimpses into how scientists will be using the ongoing flood of gene-sequencing data to customize treatments based on very specific...

45 percent of Treated Lesions Demonstrated a Durable Response Of At Least 6 Months SAN DIEGO, March 25, 2013 /PRNewswire/ -- OncoSec Medical Inc. (OTCQB: ONCS) - a company developing its advanced-stage ImmunoPulse DNA-based immunotherapy and NeoPulse therapy to treat solid tumors - announced positive, durable response results in an update on interim data from its Phase II metastatic melanoma trial. The data was presented at the HemOnc Today Melanoma and Cutaneous Malignancies...